Advertisement

European Journal of Nutrition

, Volume 57, Issue 6, pp 2227–2235 | Cite as

A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326

  • Andriana C. Kaliora
  • Ioanna Panagiota Kalafati
  • Aristea Gioxari
  • Anastasia Diolintzi
  • Alexandros Kokkinos
  • George V. DedoussisEmail author
Original Contribution
  • 226 Downloads

Abstract

Aim

To investigate the association between GCKR gene and nutritional treatment in NAFLD-related biomarkers.

Methods

This was an open-label and single-arm clinical trial in 44 overweight or obese adults with NAFLD receiving nutritional counseling for 6 months. Nutritional data, MedDietScore, clinical, biochemical, inflammatory and oxidative stress biomarkers were evaluated before and after intervention. Further, we genotyped GCKR rs1260326 and in T-allele carriers and non-Τ-carriers we assessed associations between the GCKR variant and nutritional counseling related to change in all biomarkers evaluated.

Results

Anthropometric measurements were significantly reduced after the end of the intervention in patients assigned to nutritional counseling. Liver imaging and fibrosis were significantly improved. GCKR rs1260326 T-allele frequency was 46.7%. T-carriers responded better to nutritional counseling regarding fasting blood glucose levels (mean6-0 change = −4.94 mg/dL (±9.33), p = 0.005), whereas non-T-carriers did not benefit from the intervention regarding glucose. On the other hand, levels of oxLDL decreased in the non-T-carriers group after the intervention, but not in T-carriers.

Conclusions

Our results show that GCKR rs1260326 T-allele is associated with better response of NAFLD patients to nutritional treatment regarding fasting blood glucose, but not oxLDL levels. Despite this important finding in the field of nutrigenetics, it is tricky to generalize this effect unless larger studies are conducted.

Keywords

NAFLD Nutrition Genetics GCKR Response Counseling Fasting glucose oxLDL 

Notes

Acknowledgements

I.P. Kalafati and G.V. Dedoussis were funded by “Research Project For Excellence ΙΚΥ/SIEMENS”. This study was partially funded by the “Obesity and metabolic syndrome: dietary intervention with Greek raisins in NAFLD/NASH Investigation of molecular mechanisms” reviewed and approved by the Greek Secretariat for Research and Technology (Cooperation 890/2009). Additionally, this study was reviewed by Harokopio University and “Laiko” General Hospital Athens University Medical School Institutional Review Boards.

Compliance with ethical standards

Conflict of interest

No potential conflicts of interest relevant to this article were reported.

References

  1. 1.
    Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10:686–690CrossRefPubMedGoogle Scholar
  2. 2.
    Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M (2014) Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 9(3):126–133CrossRefPubMedGoogle Scholar
  3. 3.
    Dowman JK, Tomlinson JW, Newsome PN (2010) Pathogenesis of non-alcoholic fatty liver disease. QJM 103:71–83CrossRefPubMedGoogle Scholar
  4. 4.
    Sevastianova K, Santos A, Kotronen A et al (2012) Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 96:727–734CrossRefPubMedGoogle Scholar
  5. 5.
    Shah K, Stufflebam A, Hilton TN et al (2009) Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 17:2162–2168CrossRefGoogle Scholar
  6. 6.
    Jin R, Welsh JA, Le NA, Holzberg J et al (2014) Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients 6:3187–3201CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Browning JD, Baker JA, Rogers T et al (2011) Short-term weight loss and hepatic triglyceride reduction evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 93:1048–1052CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Romeo S, Kozlitina J, Xing C, Pertsemlidis A et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Anstee QM, Day CP (2013) The genetic of NAFLD. Nat Rev Gastroenterol Hepatol 10:645–655CrossRefPubMedGoogle Scholar
  10. 10.
    Beer NL, Tribble ND, McCulloch LJ, Roos C et al (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18:4081–4088CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kitamoto A, Kitamoto T, Nakamura T, Ogawa Y et al (2014) Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 61:683–689CrossRefPubMedGoogle Scholar
  12. 12.
    Petta S, Miele L, Bugianesi E, Cammà C et al (2014) Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 9:e87523CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Tan HL, Zain SM, Mohamed R, Rampal S et al (2014) Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol 49:1056–1064CrossRefPubMedGoogle Scholar
  14. 14.
    Chambers JC, Zhang W, Sehmi J, Li X et al (2011) Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 43:1131–1138CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Vaxillaire M, Cavalcanti-Proença C, Dechaume A, Tichet J et al (2008) The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective General French Population. Diabetes 57:2253–2257CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kalafati IP, Borsa D, Dedoussis GVZ (2014) The genetics of nonalcoholic fatty liver disease: role of diet as a modifying factor. Curr Nutr Rep 3:223–232CrossRefGoogle Scholar
  17. 17.
    Santoro N, Zhang CK, Zhao H, Pakstis AJ et al (2012) Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55:781–789CrossRefPubMedGoogle Scholar
  18. 18.
    Rousseaux J, Duhamel A, Dumont J, Dallongerville J et al (2015) The n-3 long-chain PUFAs modulate the impact of the GCKR Pro446Leu polymorphism on triglycerides in adolescents. J Lipid Res 56(9):1774–1780CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Singh D, Das CJ, Baruah MP (2013) Imaging of non alcoholic fatty liver disease: a road less travelled. Indian J Endocrinol Metab 17(6):990–995CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Angulo P, Hui JM, Marchesini G, Bugianesi E et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45(4):846–854CrossRefPubMedGoogle Scholar
  21. 21.
    Panagiotakos DB, Pitsavos C, Arvaniti F, Stefanadis C (2007) Adherence to the Mediterranean food pattern predicts the prevalence of hypertension hypercholesterolemia diabetes and obesity among healthy adults the accuracy of the MedDietScore. Prev Med 44:335–340CrossRefPubMedGoogle Scholar
  22. 22.
    International HapMap Consortium (2003) The international HapMap project. Nature 426:789–796CrossRefGoogle Scholar
  23. 23.
    Jung SY, Sobel EM, Papp JC, Crandall JC et al (2016) Obesity and associated lifestyles modify the effect of glucose metabolism-related genetic variants on impaired glucose homeostasis among postmenopausal women. Genet Epidemiol 40:520–530CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yesilova Z, Yaman H, Oktenli C, Ozcan A et al (2005) Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 100:850–855CrossRefPubMedGoogle Scholar
  25. 25.
    Lieber CS (2004) CYP2E1: from ASH to NASH. Hepatol Res 28:1–11CrossRefPubMedGoogle Scholar
  26. 26.
    Anstee QM, Goldin RD (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87:1–16CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002). Circulation 106:3143Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Andriana C. Kaliora
    • 1
  • Ioanna Panagiota Kalafati
    • 1
  • Aristea Gioxari
    • 2
  • Anastasia Diolintzi
    • 1
  • Alexandros Kokkinos
    • 2
  • George V. Dedoussis
    • 1
    Email author
  1. 1.Department of Dietetics and Nutritional Science, School of Health Science and EducationHarokopio UniversityAthensGreece
  2. 2.First Department of Propaedeutic and Internal Medicine, Laiko General Hospital AthensUniversity Medical SchoolAthensGreece

Personalised recommendations